EU Accelerated Assessment Tracker

Fast-Track Success For Origin Biosciences’ Rare Disease Drug Fosdenopterin

The filing for Origin Biosciences’ fosdenopterin (Nulibry) is being fast-tracked at the European Medicines Agency. The outcomes of accelerated assessment requests from Janssen and Sanofi for teclistamab and nirsevimab respectively appear not yet to be in the public domain.

More from Europe

More from Geography